Canada Approves Kalydeco for Infants and Children With R117H Mutation
Health Canada has approved Vertex Pharmaceuticals’ Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in patients 4 months to 18 years old who carry the R117H mutation in the CFTR gene, and who weigh at least five kilograms (about 11 pounds). “It’s been our goal to ensure that…